Tempest Therapeutics (NASDAQ: TPST) — Perfil da empresa, notícias e dados financeiros
Tempest Therapeutics develops small molecule therapeutics targeting cancer biology and inflammation to address unmet medical needs.

Tempest Therapeutics
Tempest Therapeutics (NASDAQ:TPST) is focused on discovering and developing a diverse portfolio of small molecule therapeutics. Their work is dedicated to addressing a wide range of diseases with significant unmet medical needs. Central to their operations are innovative projects aimed at targeting key pathways in cancer biology, immune-oncology, and inflammation. By leveraging cutting-edge science, Tempest aims to advance these therapeutics from conception through clinical development, with the objective of bringing transformative treatments to patients worldwide. Their commitment to research and development underscores a broader mission to improve healthcare outcomes and enhance the quality of life for patients grappling with serious diseases.
Resumo
Operações
Produtos e/ou serviços de Tempest Therapeutics
- TPST-1120, a selective PPARa antagonist aimed at treating various cancers by targeting tumor and immune cells.
- TPST-1495, a dual EP2/EP4 antagonist for solid tumors, enhancing antitumor immunity.
- Preclinical programs focusing on novel targets in immuno-oncology to stimulate the immune system against cancer.
- Collaboration projects for the development and commercialization of proprietary oncology therapies.
- Research initiatives to identify and validate next-generation targets in cancer therapy.
equipe executiva do Tempest Therapeutics
- Matthew AngelPresident, CEO & Director
- Constance AmesCFO, Principal Financial & Accounting Officer, Treasurer, and Corporate Secretary
- Andrew FangHead of Business Development
Últimas notícias sobre a Tempest Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Tempest Therapeutics, em USD.
- Cap. de mercado
- 8,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -3.9
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -26,6 mi | -26,3 mi | |
| 0 | -42 mi | -41,8 mi | |
| 0 | -29,2 mi | -29,5 mi | |
| 0 | -34,6 mi | -35,7 mi |